Smith-Apeldoorn SY

Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands.

11 papers · ORCID

ArticleKetamine

Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.

Massetti S, Smith-Apeldoorn SY, Veraart JKE +6

Europe PMC2026
ArticleKetamine

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Lima Constantino J, Freimann TS, van Dalfsen JH +5

Europe PMC2026
ArticleKetamine

The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.

Coerts DT, Smith-Apeldoorn SY, Oude Nijhuis JC +6

Europe PMC2026
ArticleKetamine

A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +1

Europe PMC2026
ArticleKetamine

ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.

Oude Nijhuis JC, Coerts DT, van Dalfsen JH +6

Europe PMC2025
ArticleKetamine

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Veraart JK, Smith-Apeldoorn SY, van der Meij A +3

Europe PMC2025
ArticleKetamine

Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.

Veraart JKE, Vos CF, Punt NC +6

Europe PMC2025
ArticleKetamine

Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.

Veraart JKE, Smith-Apeldoorn SY, Kamphuis J +2

Europe PMC2025
ArticleKetamine

Oral Esketamine as Alternative for Maintenance Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Case Series.

Coerts DT, Veraart JKE, Kamphuis J +3

Europe PMC2025
ArticleKetamine

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Smith-Apeldoorn SY, Veraart JKE, Kamphuis J +5

Europe PMC2024
ArticlePsilocybin

Psychedelics for the treatment of depression, anxiety, and existential distress in patients with a terminal illness: a systematic review.

Schimmers N, Breeksema JJ, Smith-Apeldoorn SY +3

Europe PMC2022